Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

To evaluate the effect of ruboxistaurin, an orally administered protein kinase C beta (PKC beta) isozyme-selective inhibitor, on vision loss in patients with diabetes. Thirty-six-month, randomized, double-masked, placebo-controlled, parallel, multicenter trial. Six hundred eighty-five patients rando...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Ophthalmology (Rochester, Minn.) Ročník 113; číslo 12; s. 2221
Hlavní autoři:	Aiello, Lloyd Paul, Davis, Matthew D, Girach, Aniz, Kles, Keri A, Milton, Roy C, Sheetz, Matthew J, Vignati, Louis, Zhi, Xin Eric
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.12.2006
Témata:	Administration, Oral Adult Aged Aged, 80 and over Diabetic Retinopathy - drug therapy Disease Progression Double-Blind Method Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Humans Indoles - adverse effects Indoles - therapeutic use Macular Edema - drug therapy Macular Edema - physiopathology Male Maleimides - adverse effects Maleimides - therapeutic use Middle Aged Protein Kinase C - antagonists & inhibitors Protein Kinase C beta Vision Disorders - prevention & control Visual Acuity - drug effects
ISSN:	1549-4713, 1549-4713
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!